Skip to main content
SpringerLink
Log in

A Review on Imiquimod Therapy and Discussion on Optimal Management of Basal Cell Carcinomas

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Basal cell carcinoma (BCC) is the most common type of skin cancer with an increasing incidence. However, it is still poorly researched compared to many other human diseases. Today, cutaneous neoplasms are a frequent, major problem faced by medical professionals. BCC tumors can cause extensive cosmetic distress as well as disfigurement to patients especially when on the face. Treatment options include surgery, systemic agents, and topical agents. Over the past few decades more studies have been performed to evaluate the utility of topical imiquimod therapy for treatment of BCC. Imiquimod is a toll-like receptor that modifies the immune response via the up-regulation of cytokines and has the capacity to improve a person’s immune response. Multiple clinical studies have demonstrated the ability of topical imiquimod to diminish or even eradicate basal cell carcinoma. Given this variety of treatment options and the need for noninvasive options, this review is focused on summarizing the existing information available on the use of imiquimod for BCC and comparing it to other treatment modalities. While excision is the first line treatment and often has greater success with regards to clearance, imiquimod has been shown to be an efficacious treatment modality for BCC. Imiquimod therapy has been shown to be a less invasive and cheaper option than many other treatment modalities. It may be used as either monotherapy or in combination with other treatments, though occlusion has not been shown to be helpful. Several dosing regimens have been studied in the literature. Dosing should take into account factors such as the type of BCC, location, and physician/patient comfort with the regimen. Variability in response to treatment with imiquimod amongst studies suggests that response to treatment may depend on location of lesion, thus more research must be done in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Verkouteren JA, Ramdas KH, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol. 2017. https://doi.org/10.1111/bjd.15321.

    Article  PubMed  Google Scholar 

  2. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12(3):299–305. https://doi.org/10.1038/ncb2031.

    Article  CAS  PubMed  Google Scholar 

  3. Olsen CM, Wilson LF, Green AC, Bain CJ, Fritschi L, Neale RE, et al. Cancers in Australia attributable to exposure to solar ultraviolet radiation and prevented by regular sunscreen use. Aust N Z J Public Health. 2015;39(5):471–6. https://doi.org/10.1111/1753-6405.12470.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24(5 Pt 1):715–9.

    Article  CAS  PubMed  Google Scholar 

  5. Cigna E, Tarallo M, Maruccia M, Sorvillo V, Pollastrini A, Scuderi N. Basal cell carcinoma: 10 years of experience. J Skin Cancer. 2011;2011:476362. https://doi.org/10.1155/2011/476362.

    Article  PubMed  Google Scholar 

  6. Kelleners-Smeets NW, Mosterd K, Nelemans PJ. Treatment of low-risk basal cell carcinoma. J Invest Dermatol. 2017;137(3):539–40. https://doi.org/10.1016/j.jid.2016.11.021.

    Article  CAS  PubMed  Google Scholar 

  7. Luz FB, Ferron C, Cardoso GP. Analysis of effectiveness of a surgical treatment algorithm for basal cell carcinoma. Anais brasileiros de dermatologia. 2016;91(6):726–31. https://doi.org/10.1590/abd1806-4841.20165919.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Karabulut GO, Kaynak P, Ozturker C, Fazil K, Ocak OB, Taskapili M. Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. Indian J Ophthalmol. 2017;65(1):48–51. https://doi.org/10.4103/ijo.IJO_958_16.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma—a review of the literature. Acta Oncologica (Stockholm, Sweden). 1996;35(6):677–82.

    Article  CAS  PubMed  Google Scholar 

  10. Caron J, Dereure O, Kerob D, Lebbe C, Guillot B. Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol. 2009;161(3):702–3. https://doi.org/10.1111/j.1365-2133.2009.09359.x.

    Article  CAS  PubMed  Google Scholar 

  11. Yin VT, Esmaeli B. Targeting the hedgehog pathway for locally advanced and metastatic basal cell carcinoma. Curr Pharm Des. 2017;23(4):655–9. https://doi.org/10.2174/1381612822666161208100325.

    Article  CAS  PubMed  Google Scholar 

  12. Lien MH, Sondak VK. Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer. 2011;2011:571734. https://doi.org/10.1155/2011/571734.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Doan HQ, Silapunt S, Migden MR. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma. OncoTargets Ther. 2016;9:5671–8. https://doi.org/10.2147/ott.s108171.

    Article  CAS  Google Scholar 

  14. Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL. Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma. JAMA Dermatol. 2016;152(5):527–32. https://doi.org/10.1001/jamadermatol.2015.4330.

    Article  PubMed  Google Scholar 

  15. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9. https://doi.org/10.1056/NEJMoa1113713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Strom TJ, Caudell JJ, Harrison LB. Management of BCC and SCC of the head and neck. Cancer Control. 2016;23(3):220–7.

    Article  PubMed  Google Scholar 

  17. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431–8. https://doi.org/10.1001/archdermatol.2009.291.

    Article  CAS  PubMed  Google Scholar 

  18. Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614–9. https://doi.org/10.1016/j.jid.2016.10.019.

    Article  CAS  PubMed  Google Scholar 

  19. Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96–105. https://doi.org/10.1016/s1470-2045(13)70530-8.

    Article  CAS  PubMed  Google Scholar 

  20. Ozolins M, Williams HC, Armstrong SJ, Bath-Hextall FJ. The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials. 2010;11:42. https://doi.org/10.1186/1745-6215-11-42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tinelli M, Ozolins M, Bath-Hextall F, Williams HC. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol. 2012;12:19. https://doi.org/10.1186/1471-5945-12-19.

    Article  PubMed  PubMed Central  Google Scholar 

  22. van der Geer S, Martens J, van Roij J, Brand E, Ostertag JU, Verhaegh ME, et al. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. Br J Dermatol. 2012;167(1):110–5. https://doi.org/10.1111/j.1365-2133.2012.10924.x.

    Article  CAS  PubMed  Google Scholar 

  23. Torres A, Niemeyer A, Berkes B, Marra D, Schanbacher C, Gonzalez S, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004;30(12 Pt 1):1462–9. https://doi.org/10.1111/j.1524-4725.2004.30504.x.

    Article  PubMed  Google Scholar 

  24. Butler DF, Parekh PK, Lenis A. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. Dermatol Surg. 2009;35(1):24–9. https://doi.org/10.1111/j.1524-4725.2008.34378.x.

    Article  CAS  PubMed  Google Scholar 

  25. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32(1):63–9.

    Article  CAS  PubMed  Google Scholar 

  26. Gaitanis G, Alexopoulos EC, Bassukas ID. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. Eur J Dermatol. 2011;21(6):952–8. https://doi.org/10.1684/ejd.2011.1524.

    Article  PubMed  Google Scholar 

  27. Roozeboom MH, Arits AH, Mosterd K, Sommer A, Essers BA, de Rooij MJ, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol. 2016;136(8):1568–74. https://doi.org/10.1016/j.jid.2016.03.043.

    Article  CAS  PubMed  Google Scholar 

  28. Lecluse LL, Spuls PI. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal. Br J Dermatol. 2015;172(1):8–10. https://doi.org/10.1111/bjd.13460.

    Article  CAS  PubMed  Google Scholar 

  29. Osiecka B, Jurczyszyn K, Ziolkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monitor. 2012;18(2):Pi5–9.

    Article  CAS  PubMed  Google Scholar 

  30. Arits AH, Spoorenberg E, Mosterd K, Nelemans P, Kelleners-Smeets NW, Essers BA. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. Br J Dermatol. 2014;171(6):1501–7. https://doi.org/10.1111/bjd.13066.

    Article  CAS  PubMed  Google Scholar 

  31. Roozeboom MH, van Kleef L, Arits AH, Mosterd K, Winnepenninckx VJ, van Marion AM, et al. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU). J Am Acad Dermatol. 2015;73(1):93–8. https://doi.org/10.1016/j.jaad.2015.03.048.

    Article  CAS  PubMed  Google Scholar 

  32. Garcia-Martin E, Gil-Arribas LM, Idoipe M, Alfaro J, Pueyo V, Pablo LE, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. Br J Ophthalmol. 2011;95(10):1393–6. https://doi.org/10.1136/bjo.2010.193078.

    Article  CAS  PubMed  Google Scholar 

  33. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia Diez A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939–47. https://doi.org/10.1111/j.1365-2133.2005.06486.x.

    Article  CAS  PubMed  Google Scholar 

  34. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722–33. https://doi.org/10.1016/j.jaad.2003.11.066.

    Article  PubMed  Google Scholar 

  35. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147(6):1227–36.

    Article  CAS  PubMed  Google Scholar 

  36. Banzhaf CA, Themstrup L, Ring HC, Mogensen M, Jemec GB. Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy. Skin Res Technol. 2014;20(2):170–6. https://doi.org/10.1111/srt.12102.

    Article  CAS  PubMed  Google Scholar 

  37. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41(6):1002–7.

    Article  CAS  PubMed  Google Scholar 

  38. Ezughah FI, Dawe RS, Ibbotson SH, Fleming CJ. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatol Treat. 2008;19(2):111–7. https://doi.org/10.1080/09546630701557965.

    Article  CAS  Google Scholar 

  39. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390–8.

    Article  PubMed  Google Scholar 

  40. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44(5):807–13. https://doi.org/10.1067/mjd.2001.113689.

    Article  CAS  PubMed  Google Scholar 

  41. Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Mohrle M, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57(4):616–21. https://doi.org/10.1016/j.jaad.2007.05.022.

    Article  PubMed  Google Scholar 

  42. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165–71.

    Article  CAS  PubMed  Google Scholar 

  43. Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol. 2007;8(1):R8. https://doi.org/10.1186/gb-2007-8-1-r8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 NW 10th Ave., RMSB 2023, Miami, FL, 33136, USA

    Preetha Kamath, Evan Darwin, Harleen Arora & Keyvan Nouri

Authors
  1. Preetha Kamath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evan Darwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harleen Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keyvan Nouri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Preetha Kamath.

Ethics declarations

Conflict of interest

The authors have no personal or institutional interest with regards to the authorship and/or publication of this manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamath, P., Darwin, E., Arora, H. et al. A Review on Imiquimod Therapy and Discussion on Optimal Management of Basal Cell Carcinomas. Clin Drug Investig 38, 883–899 (2018). https://doi.org/10.1007/s40261-018-0681-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0681-x

Search

Navigation